Peptides for Weight Loss: GLP-1 Agonists, Growth Hormone Fragments, and What the Research Shows

Several peptide classes have been studied in clinical and preclinical research for their effects on fat metabolism and body composition. The most-studied are GLP-1 receptor agonists (semaglutide, tirzepatide), which are FDA-approved prescription drugs. Below them in the research hierarchy are growth hormone-releasing peptides (CJC-1295, Ipamorelin, Tesamorelin), which affect fat metabolism indirectly through GH, and growth hormone fragment analogs (AOD-9604, HGH Fragment 176–191), which isolate the lipolytic portion of GH. These are distinct drug classes with different mechanisms, evidence bases, legal statuses, and risk profiles.

---

The three peptide classes studied for fat loss

Weight loss research covers peptides through three distinct mechanisms. Understanding the mechanism tells you the evidence base, access pathway, and what the research actually measured.

Class 1: GLP-1 receptor agonists Semaglutide and tirzepatide act on receptors in the gut and brain that regulate appetite and glucose metabolism. In controlled clinical trials, they have shown clinically significant reductions in body weight. These are FDA-approved drugs requiring a prescription — not research peptides in the traditional sense.

Class 2: Growth hormone-releasing peptides (GHRPs / GHRHs) CJC-1295, Ipamorelin, and Tesamorelin stimulate the pituitary gland to release more growth hormone. GH has downstream effects on lipolysis (fat breakdown) and lean mass preservation. Fat loss via this pathway is indirect and the body composition effect is less pronounced than GLP-1 class effects in trials.

Class 3: GH fragment analogs AOD-9604 and HGH Fragment 176–191 are derived from the C-terminus region of human growth hormone (amino acids 176–191). This fragment is believed to contain the lipolytic signaling activity of GH without the growth-promoting (IGF-1 elevating) activity. Phase 2 human trials of AOD-9604 were conducted in the early 2000s with modest results.

---

GLP-1 receptor agonists: the strongest evidence base

Semaglutide

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic) and later approved specifically for chronic weight management (Wegovy). The STEP trial series — four Phase 3 randomized controlled trials — established semaglutide's efficacy data. (Wilding et al., 2021) The STEP 1 trial reported approximately 15% mean body weight reduction over 68 weeks in adults with obesity without diabetes. (Wilding et al., 2021)

GLP-1 receptors are expressed in the hypothalamus, vagus nerve, and GI tract. Activation reduces appetite via multiple pathways: slowing gastric emptying, increasing satiety signaling, and acting on hypothalamic appetite-regulating circuits.

FDA status: Approved. Ozempic for type 2 diabetes; Wegovy for chronic weight management. Prescription required.

US access: Through a licensed prescriber. Many telehealth platforms offer semaglutide prescriptions with a compounding pharmacy fulfillment pathway for patients who don't qualify for brand-name insurance coverage.

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in a class that adds glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to the GLP-1 mechanism. The SURMOUNT-1 Phase 3 trial showed approximately 21% mean body weight reduction over 72 weeks at the highest dose in adults without diabetes. (Jastreboff et al., 2022)

GIP receptor agonism appears to enhance the appetite-suppressing and metabolic effects of GLP-1 receptor agonism. The additive mechanism produces larger effect sizes in trials compared to semaglutide alone.

FDA status: Approved. Mounjaro for type 2 diabetes; Zepbound for chronic weight management. Prescription required.

---

GH-releasing peptides: indirect fat loss via growth hormone

Growth hormone (GH) has a well-established role in lipid metabolism — it stimulates lipolysis and promotes fat oxidation, particularly visceral fat. GH secretion naturally declines with age. GH-releasing peptides work by stimulating the body's own pituitary GH production rather than administering exogenous GH.

CJC-1295

CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that extends the half-life of endogenous GHRH. It stimulates pulsatile GH release over days rather than hours. Clinical research on CJC-1295 alone for fat loss is limited. It is most frequently studied in combination with Ipamorelin, where the GHRH + GHRP pairing amplifies GH pulses through complementary receptor pathways.

Research status: Phase 1/2 human studies on GH secretion endpoints. No Phase 3 trials on body composition.

Ipamorelin

Ipamorelin is a growth hormone secretagogue receptor (GHSR) agonist. It stimulates GH release with high selectivity and minimal off-target effects on cortisol or prolactin compared to older GHRPs. In animal studies, Ipamorelin increased lean mass and reduced fat mass. Human data is primarily from GH secretion studies.

Research status: Preclinical body composition data; human data primarily on GH secretion endpoints.

Tesamorelin

Tesamorelin is an FDA-approved stabilized GHRH analog indicated for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy. Multiple Phase 3 trials in this indication showed significant visceral fat reduction as a primary endpoint.

FDA status: Approved (Egrifta SV) for HIV-associated lipodystrophy. Prescription required.

Research note: The evidence base is specific to HIV-associated lipodystrophy. Off-label use in general weight loss does not have the same controlled trial support.

---

GH fragment analogs: direct lipolytic mechanism

AOD-9604

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic analog of amino acids 177–191 of human growth hormone. It was developed to isolate the lipolytic properties of GH without triggering IGF-1 production or systemic glucose metabolism effects seen with full-length GH.

Phase 2 clinical trials conducted in the early 2000s tested AOD-9604 in adults with obesity over 12 and 24 weeks. Results showed modest weight loss versus placebo at some dose ranges in some trials. No Phase 3 trials were conducted; drug development was discontinued.

Research status: Phase 2 human trials completed; no Phase 3 data. Not FDA-approved.

Mechanism in preclinical research: Activates beta-3 adrenergic receptors and inhibits lipogenesis in vitro. Animal data shows increased fat oxidation.

HGH Fragment 176–191

Derived from the same C-terminus region of GH as AOD-9604, HGH Fragment 176–191 has been studied in cell lines and animal models for lipolytic effects. Human clinical trial data is more limited than for AOD-9604.

Research status: Predominantly preclinical. Not FDA-approved.

---

All three classes compared

---

How to find a US provider

FDA-approved peptides (semaglutide, tirzepatide, tesamorelin) and non-approved compounds accessed through the compounding pharmacy route all require a licensed prescriber. The PeptideBase directory lists verified US providers by compound:

• Semaglutide providers →
• Tirzepatide providers →
• AOD-9604 providers →
• CJC-1295 providers →
• Ipamorelin providers →
• Tesamorelin providers →

For a full breakdown of what to check before choosing a provider — license status, prescription process, compounding pharmacy identity — see How to find a legitimate peptide provider →

You can also use the PeptideBase matching tool → to find providers by goal and location.

---

Frequently asked questions

QWhat peptides are used for weight loss?

The most studied are GLP-1 receptor agonists (semaglutide, tirzepatide), which are FDA-approved prescription drugs with Phase 3 clinical trial data. Growth hormone-releasing peptides like CJC-1295 and Ipamorelin affect fat metabolism indirectly through GH release. GH fragment analogs — AOD-9604 and HGH Fragment 176–191 — have been studied specifically for lipolytic properties. These represent three distinct mechanisms with different evidence bases and access pathways.

QAre weight loss peptides FDA-approved?

Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management. Tesamorelin is FDA-approved for a specific indication (HIV-associated lipodystrophy). GH fragment peptides and most GHRP combinations are not FDA-approved for any indication.

QWhat is the difference between GLP-1 peptides and growth hormone peptides for weight loss?

GLP-1 agonists work primarily through appetite suppression — they slow gastric emptying, reduce hunger signals, and affect brain circuits around food intake. Growth hormone-releasing peptides work indirectly: by stimulating GH release, they promote lipolysis and lean mass preservation over time. The mechanisms are distinct; the evidence bases are very different in size and quality.

QWhat is AOD-9604?

AOD-9604 is a synthetic fragment of human growth hormone (amino acids 177–191) studied specifically for lipolytic effects. Phase 2 clinical trials in the early 2000s showed modest weight loss versus placebo. Development was discontinued before Phase 3. It is not FDA-approved and is not a controlled substance. In the US, it is accessible through compounding pharmacies (prescription required) and research chemical vendors.

QDo weight loss peptides require a prescription?

FDA-approved peptides (semaglutide, tirzepatide, tesamorelin) require a prescription. Non-approved compounds like AOD-9604 and GHRP combinations can be accessed through compounding pharmacies (requires a prescription) or through research chemical vendors (no prescription required, "for laboratory use only" labeling). The same two-track framework described in the BPC-157 legal status guide applies to most peptides.

QHow does semaglutide compare to tirzepatide for weight loss?

Based on separate Phase 3 trials, tirzepatide (SURMOUNT-1: ~21% body weight reduction) showed larger effect sizes than semaglutide (STEP 1: ~15% body weight reduction). (Jastreboff et al., 2022; Wilding et al., 2021) Both are once-weekly subcutaneous injections. Head-to-head trial data directly comparing the two is limited. These are research findings, not predictions for individual outcomes.

---

Browse weight-loss focused providers in the PeptideBase directory: View providers by goal →

Last reviewed: June 2026